A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
NCT03070964 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2020-10-14
Summary
Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in patients with relapsed/refractory (R/R) angioimmunoblastic Tcell lymphoma (AITL).This is an international, multicenter study (with approximately 17 investigative sites).
Conditions
Interventions
- DRUG
-
plitidepsin
Sponsors & Collaborators
-
PharmaMar
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-25
- Primary Completion
- 2018-07-31
- Completion
- 2018-07-31
Countries
- United States
- Czechia
- Italy
- Spain
Study Locations
More Related Trials
-
Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas
NCT03119467 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03369964 ·Status: WITHDRAWN ·Phase: PHASE1
-
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
NCT01822886 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
NCT06083701 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
NCT03770000 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
NCT03141203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
NCT03127020 ·Status: COMPLETED ·Phase: PHASE2
-
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
NCT04251065 ·Status: TERMINATED ·Phase: PHASE2
-
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
NCT01998035 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05083208 ·Status: TERMINATED ·Phase: PHASE1
-
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
NCT01742793 ·Status: TERMINATED ·Phase: PHASE1
-
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
NCT04774068 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
NCT02910063 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
NCT01516619 ·Status: COMPLETED ·Phase: PHASE2
-
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
NCT07018752 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
NCT01034163 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
NCT00274651 ·Status: TERMINATED ·Phase: PHASE2
-
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
NCT03120000 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
NCT03547700 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
NCT00496431 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
NCT06733441 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
NCT03120676 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
NCT03144674 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
NCT05313243 ·Status: RECRUITING ·Phase: PHASE2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
NCT02232516 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2